IRTC IRhythm Technologies Inc.

iRhythm Technologies Announces the Appointment of Renee Budig to its Board of Directors

iRhythm Technologies Announces the Appointment of Renee Budig to its Board of Directors

SAN FRANCISCO, April 23, 2020 (GLOBE NEWSWIRE) -- iRhythm Technologies, Inc. (NASDAQ: IRTC), a leading digital health care solutions company focused on the advancement of cardiac care, today announced the appointment of Renee Budig to its Board of Directors effective April 23, 2020. Ms. Budig was appointed as a Class II director and will also serve on the Audit Committee. 

“On behalf of the iRhythm team, I am delighted to welcome Renee to our Board of Directors,” said Kevin King, CEO. “Renee has a very strong finance and operations background as a leader and advisor to a number of successful technology companies. Renee will fill a key role in bringing additional experience and perspectives to iRhythm. We are looking forward to Renee’s contributions to guide iRhythm to continued success and help us scale our operations.”

On her appointment, Ms. Budig commented, “I am thrilled to join the Board of iRhythm, a recognized leader in the digital health space. iRhythm has shown a track record of innovation and is changing the status quo in cardiac monitoring. I am looking forward to contributing my expertise and helping iRhythm continue to grow and scale their digital health platform.”

Following the appointment of Ms. Budig, iRhythm’s Board is comprised of eight directors.

About Renee Budig

Ms. Budig has served as a member of the Board of Directors and as Chair of the Audit Committee of Chegg, Inc. since November 2015. Since September 2012, Ms. Budig has served as the Executive Vice President and Chief Financial Officer of CBS Interactive, a division of ViacomCBS, the world’s largest publisher of premium digital content and a perennial top 10 Internet company. Previously, Ms. Budig served as Chief Financial Officer of Hightail, Inc. (formerly branded YouSendIt and acquired by OpenText), a cloud service that allowed users to send, receive, digitally sign and synchronize files. Prior, Ms. Budig was the Vice President of Finance at Netflix, Inc. and the Vice President of Finance for Veritas Software. Ms. Budig holds a B.S. in Business Administration from the University of California, Berkeley.

                                                              

About iRhythm Technologies, Inc. 

iRhythm is a leading digital health care company redefining the way cardiac arrhythmias are clinically diagnosed. The company combines wearable biosensor devices worn for up to 14 days and cloud-based data analytics with powerful proprietary algorithms that distill data from millions of heartbeats into clinically actionable information. The company believes improvements in arrhythmia detection and characterization have the potential to change clinical management of patients.

Investor Relations Contact:

Lynn Pieper Lewis or Leigh Salvo

(415) 937-5404



                   Media Contact

Saige Smith

(262) 289-7065

   



EN
23/04/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on IRhythm Technologies Inc.

Irhythm Technologies Inc: 2 directors

A director at Irhythm Technologies Inc sold 2,555 shares at 158.970USD and the significance rating of the trade was 53/100. Is that information sufficient for you to make an investment decision? This report gives details of those trades and adds context and analysis to them such that you can judge whether these trading decisions are ones worth following. Included in the report is a detailed share price chart which plots discretionary trades by all the company's directors over the last two year...

 PRESS RELEASE

iRhythm and Lucem Health Partner to Introduce Predictive AI Solution f...

iRhythm and Lucem Health Partner to Introduce Predictive AI Solution for Early Detection of Arrhythmias in Patient Populations with Comorbid Conditions Partnership aims to utilize predictive AI to help identify arrhythmias earlier in patient populations with an elevated risk for arrhythmias to enable timely care for millions who remain undiagnosedCommercial offering from this collaboration designed to support scalable population health and value-based care strategies SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a digital health leader focused on creating trusted solut...

 PRESS RELEASE

iRhythm Technologies Announces Second Quarter 2025 Financial Results

iRhythm Technologies Announces Second Quarter 2025 Financial Results SAN FRANCISCO, July 31, 2025 (GLOBE NEWSWIRE) --  (NASDAQ: IRTC), a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today reported financial results for the three months ended June 30, 2025. Second Quarter 2025 Financial Highlights Revenue of $186.7 million, a 26.1% increase compared to second quarter 2024Gross margin of 71.2%, a 130-basis point increase compared to second quarter 2024Unrestricted cash, cash equivalents, and marketable securit...

 PRESS RELEASE

iRhythm Technologies to Report Second Quarter 2025 Financial Results o...

iRhythm Technologies to Report Second Quarter 2025 Financial Results on July 31, 2025 SAN FRANCISCO, July 17, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC), a leading digital health care company focused on creating trusted solutions that detect, prevent, and predict disease, today announced that it will release financial results for the second quarter 2025 after the close of trading on Thursday, July 31, 2025. The company’s management team will host a corresponding conference call beginning at 1:30 p.m. PT / 4:30 p.m. ET. Interested parties may access a live and archived webcast of the confere...

 PRESS RELEASE

iRhythm Technologies Announces Board Member Retirements and New Direct...

iRhythm Technologies Announces Board Member Retirements and New Director Appointments SAN FRANCISCO, July 07, 2025 (GLOBE NEWSWIRE) -- (NASDAQ:IRTC) , a leading digital health care company focused on creating trusted solutions that detect, predict, and prevent disease, today announced the retirement of two long-serving board members, Mark Rubash and Ralph Snyderman, M.D., effective July 7, 2025. Concurrently, Karen McGinnis and Kevin O’Boyle have accepted appointments to the board of directors. Mark Rubash has served on the board since 2016, prior to the company’s initial public offerin...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch